News

It now seems so long ago that Pfizer (NYSE: PFE) became the first company in the biopharmaceutical industry to generate over $100 billion in annual sales. The drugmaker achieved this milestone

Even very well-run companies will eventually fall upon hard times. That's the backstory you need to keep in mind when you examine Bristol Myers Squibb (NYSE: BMY) and Pfizer (NYSE: PFE). Here's why

Two pieces of encouraging news from Voyager Technologies (NYSE: VOYG) over the last several days have been propelling the company's shares higher. According to data compiled by S&P Global Market

Novavax (NASDAQ: NVAX) was once a leading contender to dominate the coronavirus vaccine market. The company faced several challenges, however, and although it successfully launched its vaccine

AbbVie (NYSE: ABBV), a pharmaceutical leader, has faced some challenges over the past three years. The company is managing some patent cliffs and clinical setbacks that worried investors and dinged

This bioproduction tools provider for cell and gene therapy reported a notable insider sale amid a modestly downtrending share price.

Troy Wichterman, Chief Financial Officer of BioLife Solutions (N

Are you looking for a top growth stock to buy heading into 2026? Although valuations are high for many stocks, there are some potential deals still out there right now.

Three stocks that haven't

Voyager Technologies (NYSE: VOYG) took its investors on the kind of voyage they enjoy on Wednesday. The space and defense company's stock took off that day, closing the trading session more than 8%

There's an old saying that a rising tide lifts all ships. Ironically enough, the adage doesn't apply to cruise line stocks. Norwegian Cruise Line (NYSE: NCLH) is once again the worst-performing

If you see news about the pharmaceutical industry today and it isn't directly about GLP-1 weight loss drugs, it's likely to include at least a mention of this new class of medications. GLP-1 drugs

AST SpaceMobile (NASDAQ: ASTS) was a bad investment from 2020 to the start of 2024. The stock woefully underperformed the S&P 500 during that stretch and went from $20 per share to $2 per share

Those who had the foresight to invest in Summit Therapeutics (NASDAQ: SMMT) and Madrigal Pharmaceuticals (NASDAQ: MDGL) three years ago are sitting pretty right now. Both companies have soared over

Pfizer (NYSE: PFE) is deeply unloved today. There are a couple of reasons for this that are important, but the big story revolves around the company's drug portfolio. With three drugs facing patent

Summit Street Capital Management established a new position in Weatherford International (NASDAQ:WFRD), adding 398,661 shares valued at an estimated $27.3 million during the third quarter, according

On November 14, New York City-based Summit Street Capital Management disclosed a new position in Signet Jewelers (NYSE:SIG), acquiring 264,054 shares valued at $25.3 million, according to its latest

New York City-based Summit Street Capital Management increased its stake in Core Natural Resources (NYSE:CNR) by 81,170 shares in the third quarter, adding approximately $10.4 million in position

New York City-based Summit Street Capital Management fully exited its position in Kulicke and Soffa Industries, Inc. (NASDAQ:KLIC), reducing holdings by 281,812 shares during the quarter and

After months of uncertainty, President Donald Trump announced that the U.S. government would permit Nvidia (NASDAQ: NVDA) to sell its H200 processors to China. Trump announced the decision in a post

After lagging the market over the past couple of years, Merck (NYSE: MRK) has experienced a slight rebound in the last month, thanks to several positive developments. The stock has increased by 20%

In today's video, I discuss recent updates affecting Intel (NASDAQ: INTC), Nvidia (NASDAQ: NVDA), Advanced Micro Devices (NASDAQ: AMD), and other artificial intelligence (AI) stocks. To learn more,

In today's video, I discuss recent updates affecting Advanced Micro Devices (NASDAQ: AMD) and other artificial intelligence (AI) stocks. To learn more, check out the short video, consider

Nvidia (NASDAQ: NVDA) stock gained 2.3% in after-hours trading on Monday, following President Donald Trump's reportedly posting on Truth Social that the U.S. government will allow Nvidia to export

Foresite Capital Management IV, LLC disclosed a new stake in Cytokinetics (NASDAQ:CYTK), adding 458,295 shares valued at $25.19 million as of Sept. 30, 2025. The move was detailed in a quarterly